ARMISTICE CAPITAL, LLC - 03 Feb 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
10%+ Owner
Signature
ARMISTICE CAPITAL, LLC, Name: /s/ Steven Boyd, Title: Managing Member
Issuer symbol
AVTX
Transactions as of
03 Feb 2023
Net transactions value
+$1,319
Form type
4
Filing time
09 Feb 2023, 15:32:03 UTC
Previous filing
19 May 2022
Next filing
28 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Small acquisition under Rule 16a-6 $1,319 +334 +0.01% $3.95* 3,965,000 03 Feb 2023 See Footnote F1, F2
transaction AVTX Common Stock Purchase +450,000 +11% 4,415,000 07 Feb 2023 See Footnote F1, F2, F3
holding AVTX Common Stock 34,370 03 Feb 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Warrant Purchase +450,000 450,000 07 Feb 2023 Common Stock 450,000 $5.00 See Footnote F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amount reflects the effect of the 1-for-12 reverse stock split.
F2 The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3 Each share of common stock and accompanying warrant were purchased together for $3.98. The warrants are subject to a 4.99% beneficial ownership limitation on exercise.
F4 These shares are directly owned by Mr. Boyd in his personal capacity.